Journal article

Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations

Doen Ming Ong, Michael Ashby, Andrew Grigg, Grace Gard, Zi Y Ng, Huayi Ellen Huang, Yee Shuen Chong, Chan Yoon Cheah, Bianca Devitt, Geoffrey Chong, Zoe Loh, Allison Mo, Eliza A Hawkes

British Journal of Haematology | WILEY | Published : 2019


Elderly patients may be heterogeneous in their abilities to tolerate immunochemotherapy-associated toxicities. We describe the morbidity of rituximab-chemotherapy combinations among 205 newly-diagnosed diffuse large B-cell lymphoma (DLBCL) patients aged ≥60 years from 3 tertiary hospitals between 2009 and 2016, and explore the utility of retrospectively-assigned baseline Comprehensive Geriatric Assessment (CGA) in predicting these toxicities. Seventy-three percent (146/201) experienced grade ≥3 toxicities, 81% (163/201) needed admission, 52% (107/205) had ≥2 unplanned admissions, 82/201 (41%) required dose reductions (DR) subsequent to Cycle 1, 39/166 (23%) had chemotherapy delays and 26/198..

View full abstract